AU2013312120B2 - Compositions and methods for treating cutaneous scarring - Google Patents

Compositions and methods for treating cutaneous scarring Download PDF

Info

Publication number
AU2013312120B2
AU2013312120B2 AU2013312120A AU2013312120A AU2013312120B2 AU 2013312120 B2 AU2013312120 B2 AU 2013312120B2 AU 2013312120 A AU2013312120 A AU 2013312120A AU 2013312120 A AU2013312120 A AU 2013312120A AU 2013312120 B2 AU2013312120 B2 AU 2013312120B2
Authority
AU
Australia
Prior art keywords
seq
scar
polypeptide
dressing
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013312120A
Other languages
English (en)
Other versions
AU2013312120A1 (en
Inventor
Colleen Brophy
Cynthia Lander
Caryn Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of AU2013312120A1 publication Critical patent/AU2013312120A1/en
Assigned to MOERAE MATRIX, INC. reassignment MOERAE MATRIX, INC. Request for Assignment Assignors: BROPHY, COLLEEN, LANDER, CYNTHIA, MOERAE MATRIX, INC., PETERSON, CARYN
Application granted granted Critical
Publication of AU2013312120B2 publication Critical patent/AU2013312120B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2013312120A 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring Ceased AU2013312120B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261699160P 2012-09-10 2012-09-10
US61/699,160 2012-09-10
US13/829,876 2013-03-14
US13/829,876 US20140072613A1 (en) 2012-09-10 2013-03-14 Compositions and Methods for Treating Cutaneous Scarring
PCT/US2013/059060 WO2014040074A2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Publications (2)

Publication Number Publication Date
AU2013312120A1 AU2013312120A1 (en) 2015-03-26
AU2013312120B2 true AU2013312120B2 (en) 2018-04-19

Family

ID=50233502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013312120A Ceased AU2013312120B2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Country Status (14)

Country Link
US (1) US20140072613A1 (https=)
EP (1) EP2892546A4 (https=)
JP (1) JP6247692B2 (https=)
KR (1) KR102040710B1 (https=)
CN (1) CN105120886A (https=)
AU (1) AU2013312120B2 (https=)
CA (1) CA2884264A1 (https=)
GB (1) GB2520897B (https=)
HK (2) HK1210422A1 (https=)
MX (1) MX368878B (https=)
NZ (1) NZ705743A (https=)
RU (2) RU2705211C2 (https=)
SG (1) SG11201501818VA (https=)
WO (1) WO2014040074A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
GB2524707B (en) 2013-01-09 2020-04-22 Int Stem Cell Corporation Small molecules that promote skin regeneration
WO2015084897A2 (en) * 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016112292A1 (en) * 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
CN104689301A (zh) * 2015-03-27 2015-06-10 吴开刚 一种祛除妊娠纹的药物及其制备方法
JP7187310B2 (ja) * 2015-10-08 2022-12-12 エーエムディー セラピューティックス エルエルシー Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
CN105709270B (zh) * 2016-03-18 2019-01-01 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
JP6815782B2 (ja) * 2016-07-29 2021-01-20 小林製薬株式会社 α−ＳＭＡ産生抑制剤
US11697813B2 (en) 2016-10-30 2023-07-11 Sirnaomics, Inc. Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
CN111163784B (zh) * 2017-09-01 2024-07-26 黄玲惠 用于治疗蟹足肿的药物组合物及其用途
US10485755B1 (en) * 2018-02-05 2019-11-26 Wade Cheng Formulation and method for treatment of non-acne scars
CN112074596A (zh) * 2018-02-09 2020-12-11 亥姆霍兹慕尼黑-德国健康与环境研究中心(有限公司) 监测疤痕形成的装置和方法
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
ES2980620T3 (es) 2018-05-16 2024-10-02 Univ Leland Stanford Junior Administración controlada en hidrogel de inhibidor de la cinasa de adhesión focal para disminuir la formación de cicatrices
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
WO2020210382A1 (en) * 2019-04-08 2020-10-15 The General Hospital Corporation Enhancement of melanocyte migration using rock inhibitors
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
CN114072163A (zh) * 2019-05-09 2022-02-18 芝加哥大学 皮肤伤口愈合和瘢痕预防的新材料
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179B (zh) * 2019-12-19 2021-04-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
KR102584738B1 (ko) * 2020-01-17 2023-10-06 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
US12360428B2 (en) * 2020-04-13 2025-07-15 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法
CN113143524A (zh) * 2021-04-13 2021-07-23 王伟 一种用于构建微创兔膝关节炎模型的穿刺系统
CN117295512A (zh) * 2021-05-03 2023-12-26 爱恩斯生物有限公司 用于改善瘢痕和瘢痕瘤的包含zag衍生的肽的组合物
WO2023009439A1 (en) * 2021-07-30 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
KR102696817B1 (ko) * 2023-07-06 2024-08-21 주식회사 아루다 히알루론산, 프로테오글리칸, 글리코사미노글리칸, 아텔로콜라겐, 베타글루칸, 유비퀴논 및 비타민 e를 포함하는 에스테틱 조성물 및 이의 제조 방법
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149389A1 (en) * 2007-01-10 2009-06-11 Purdue Research Foundation Kinase Inhibitors And Uses Thereof
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
WO2011160055A2 (en) * 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
WO2012106508A1 (en) * 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2200557C1 (ru) * 2001-11-23 2003-03-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н.Федорова Способ лечения гипертрофических и келоидных рубцов
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
DK2617431T3 (en) 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
CA2699868A1 (en) * 2007-09-19 2009-03-26 Surmodics, Inc. Biocompatible foams, systems, and methods
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US8593698B2 (en) * 2009-02-26 2013-11-26 Hewlett-Packard Development Company, L.P. Void pantographs and methods for generating the same using at least one test void pantograph
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090149389A1 (en) * 2007-01-10 2009-06-11 Purdue Research Foundation Kinase Inhibitors And Uses Thereof
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
WO2011160055A2 (en) * 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
WO2012106508A1 (en) * 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)

Also Published As

Publication number Publication date
KR20150100615A (ko) 2015-09-02
GB2520897B (en) 2020-07-01
US20140072613A1 (en) 2014-03-13
GB201505972D0 (en) 2015-05-20
CN105120886A (zh) 2015-12-02
EP2892546A4 (en) 2016-07-13
RU2705211C2 (ru) 2019-11-06
CA2884264A1 (en) 2014-03-13
JP2015533798A (ja) 2015-11-26
WO2014040074A3 (en) 2014-06-26
SG11201501818VA (en) 2015-04-29
WO2014040074A2 (en) 2014-03-13
JP6247692B2 (ja) 2017-12-13
HK1210414A1 (en) 2016-04-22
EP2892546A2 (en) 2015-07-15
AU2013312120A1 (en) 2015-03-26
GB2520897A (en) 2015-06-03
RU2015113011A (ru) 2016-11-10
HK1210422A1 (en) 2016-04-22
NZ705743A (en) 2018-08-31
MX368878B (es) 2019-10-21
KR102040710B1 (ko) 2019-11-05
RU2019126644A (ru) 2019-09-19
MX2015003075A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
AU2013312120B2 (en) Compositions and methods for treating cutaneous scarring
Vorotnikova et al. Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo
KR101830926B1 (ko) 피부 노화를 방지 및/또는 개선하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
JP2017148075A (ja) 創傷治癒組成物および治療
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
US20110236325A1 (en) Methods to treat or prevent a skin condition using a nell1 peptide
KR102527367B1 (ko) 탄력섬유의 생체 내 합성
EP3413881B1 (en) Compositions and methods for treating chronic wounds
Watanabe et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding
JP2015513905A (ja) カドヘリン調節に基づく組成物および処置
TWI353849B (en) Methods and compositions for the promotion of hair
JP2017513944A (ja) 異常な皮膚瘢痕化の治療
KR100341793B1 (ko) 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
KR20250058279A (ko) 피부 흉터 형성을 치료하기 위한 조성물 및 방법
JP6469767B2 (ja) 皮膚老化を予防及び／又は改善するためのｐｅｄｆ−由来ポリペプチドの使用
US20140274872A1 (en) Compositions and treatments based on cadherin modulation
WO2021241428A1 (ja) エラスチン産生促進剤及び皮膚化粧料
Adib et al. 614 modulation of NK cell activation by calcium from alginate dressings in vitro
Lapthorn et al. 616 Investigating if hydroxypyridone anti-fungals can target already established myofibroblasts in an in vitro model of hypertrophic scarring
Mias-Vigouroux et al. 619 Preventive effect of a dermocosmetic product containing an active ingredient complex, Cicahyalumide® and Rhealba® Oat plantlets extract, on stretch mark appearance
Jinnin et al. 615 yRNA4 up-regulation induces collagen expression in scleroderma cultured dermal fibroblasts
Stegemann et al. 617 Endothelial to mesenchymal transition-a novel field of action of the alpha7 nicotinic acetylcholine receptor?
Williamson et al. Relaxin-2 drives regenerative healing and suppresses scar formation
T HE Conjoint 3rd Australasian Wound & Tissue Repair Society and 9th Australasian Society for Dermatology Research Conference Sydney Australia May 22–24, 2012
Copenhagen 7th Joint Meeting of the European Tissue Repair Society (ETRS) with the Wound Healing Society

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MOERAE MATRIX, INC.

Free format text: FORMER APPLICANT(S): BROPHY, COLLEEN; LANDER, CYNTHIA; MOERAE MATRIX, INC.; PETERSON, CARYN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired